Dynamic intracellular survivin in oral squamous cell carcinoma:: underlying molecular mechanism and potential as an early prognostic marker

被引:105
作者
Engels, K.
Knauer, S. K.
Metzler, D.
Simf, C.
Struschka, O.
Bier, C.
Mann, W.
Kovacs, A. F.
Stauber, R. H.
机构
[1] Univ Hosp Mainz, Dept Otorhinolaryngol Mol & Cellular Oncol, D-55101 Mainz, Germany
[2] Univ Hosp Frankfurt, Dept Oral & Maxillofacial Plast Surg, Frankfurt, Germany
[3] Goethe Univ Frankfurt, Inst Informat, Frankfurt, Germany
[4] Georg Speyer Haus, Frankfurt, Germany
[5] Univ Hosp Frankfurt, Dept Pathol, Frankfurt, Germany
关键词
head and neck cancer; apoptosis; cancer therapy; cell cycle;
D O I
10.1002/path.2134
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Survivin functions as an apoptosis inhibitor and a regulator of cell division in many tumours. The intracellular localization of survivin in tumours has been suggested as a prognostic marker. However, current reports are inconsistent and the underlying molecular mechanisms are not understood. The present study has examined the localization and prognostic value of nuclear and cytoplasmic survivin in the pre-therapeutic biopsies from 71 oral and oropharyingeal squamous carcinoma (OSCC) patients. Statistical analysis indicated that preferential nuclear versus cytoplasmic survivin correlated with favourable versus unfavourable disease outcome. Uni- and multi-variate analysis showed that in contrast to total survivin expression, the difference between nuclear and cytoplasmic survivin was a strong predictor for relapse-free survival (p = 0.0003). As a potential underlying molecular mechanism, it is shown in OSCC cell lines that predominantly cytoplasmic survivin mediates protection against chemo- and radio-therapy-induced apoptosis. Importantly, the cytoplasmic localization of survivin is regulated by its nuclear export signal (NES), and export-deficient nuclear survivin is not cytoprotective. This study suggests that the difference between cytoplasmic and nuclear survivin is an indicator for survivin activity in tumour cells. Thus, this difference may serve as a predictive marker of outcome in OSCC patients undergoing multi-modality therapy. The pharmacogenetic interference with survivin's cytoplasmic localization is also to be pursued as a potential therapeutic strategy. Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:532 / 540
页数:9
相关论文
共 32 条
  • [1] Targeted therapy by disabling crossroad signaling networks:: the survivin paradigm
    Altieri, DC
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (03) : 478 - 482
  • [2] Validating survivin as a cancer therapeutic target
    Altieri, DC
    [J]. NATURE REVIEWS CANCER, 2003, 3 (01) : 46 - 54
  • [3] Crm1 is a mitotic effector of Ran-GTP in somatic cells
    Arnaoutov, A
    Azuma, Y
    Ribbeck, K
    Joseph, J
    Boyarchuk, Y
    Karpova, T
    McNally, J
    Dasso, M
    [J]. NATURE CELL BIOLOGY, 2005, 7 (06) : 626 - U27
  • [4] BARNES L, 2005, PATHOLOGY GENETICS H, V9, P163
  • [5] Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues
    Chui, X
    Egami, H
    Yamashita, J
    Kurizaki, T
    Ohmachi, H
    Yamamoto, S
    Ogawa, M
    [J]. BRITISH JOURNAL OF CANCER, 1996, 73 (10) : 1233 - 1236
  • [6] Separating the anti-apoptotic and mitotic roles of survivin
    Colnaghi, Rita
    Connell, Claire M.
    Barrett, Rachel M. A.
    Wheatley, Sally P.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (44) : 33450 - 33456
  • [7] Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters
    Ferrandina, G
    Legge, F
    Martinelli, E
    Ranelletti, FO
    Zannoni, GF
    Lauriola, L
    Gessi, M
    Gallotta, V
    Scambia, G
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (02) : 271 - 277
  • [8] Nucleocytoplasmic transport in apoptosis
    Ferrando-May, E
    [J]. CELL DEATH AND DIFFERENTIATION, 2005, 12 (10) : 1263 - 1276
  • [9] Is there a new role for induction chemotherapy in the treatment of head and neck cancer?
    Forastiere, AA
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (22): : 1647 - 1649
  • [10] Forastiere Arlene A, 2005, J Natl Compr Canc Netw, V3, P316